Mass Balance Study of FYU-981

Phase 2 Completed 6 enrolled Fuji Yakuhin Co., Ltd. Mochida Pharmaceutical Company, Ltd. · collab

NaSingle-groupOpen-labelBasic science

Summary

To assess the plasma pharmacokinetics, the routes extent of elimination, and the metabolites of FYU-981 after a single 1 mg oral dose of 14C-FYU-981 in healthy male subjects.

Timeline

Start: 2016-09
Primary completion: 2017-01
Completion: 2018-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Dotinurad	Small molecule	1 mg	Oral

Indications

No indication recorded.